Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.36 -0.06 (-1.11%) Market Cap: 766.59 Mil Enterprise Value: 543.79 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 72/100

Aurinia Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 20, 2021 / 06:55PM GMT
Release Date Price: $20.91 (-0.43%)
Justin Kim
Oppenheimer & Co. Inc. - Analyst

Hi, good afternoon, everyone. Thanks for joining us today for Aurinia Pharmaceuticals' presentation at the Oppenheimer Fall Healthcare Summit. It's my pleasure to welcome Mr. Peter Greenleaf, CEO, who will present on the Company and have a nice conversation following.

Peter Greenleaf
Aurinia Pharmaceuticals Inc. - CEO & Director

Hey, Justin. And I want to thank everybody at Oppenheimer for having us, and for everybody who's listening live, good afternoon. We're excited to be here and excited to take 20, 30 minutes to walk you through where we are as a company and then go to questions with Justin if we have time left over. But obviously before I jump into it, I just want to point you to our forward-looking statements and also point you to our Internet site at Aurinia.com for our most recent filings with the SEC.

So who is Aurinia today? And while we've been around for about a decade, I can tell you we've been busy the last several years moving the Company from a development stage organization to one

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot